Our discovery of the CDCP1-Src axis as a new component of HGF-Met signaling provides insights into the regulatory mechanisms underlying the multifaceted functions of HGF during morphogenesis and/or regenerative growth, and might contribute to the development of more promising therapies for malignant cancers that are associated with the up-regulation of CDCP1 and Met. This evidence concerns the gene MET and cancer.